
usd pm et
summari pharmaceut compani rank one world largest produc gener drug
biosimilar treatment
nm price-to-earnings oper ep
oper typic pharmaceut risk includ
uncertainti stem program
regulatori approv process also see uniqu risk
gener produc like base develop
countri firm domicil lower-cost emerg
market countri like india gain signific market
share develop nation view signific legal
risk often aris well stem product liabil
govern investig improp market
practic think mitig risk
success histori develop high-barri gener
fiscal year end dec ep estim base cfra
oper earn histor earn report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
stock trade
full-year revenu increas
due yoy declin european sale
revenu result lower price
partial off-set strong growth rest
world revenu yoy due
higher sale exist product japan
emerg market new product sale
mainli australia
 america sale yoy
revenu due weaker sale exist
product lower price result
intensifi gener competit low-cost
pose seriou threat view sale
new product wixela inhub fulphila
yulperi help off-set trend
juli announc plan merg
upjohn sharehold own
new entiti viatri merger expect
close howev see high
integr risk think deal fail
rapid declin upjohn sale fell
yoy gener brand lyrica
enter market even exclud lyrica
recommend hold previous
believ pipelin complex gener
biosimilar multi-billion dollar brand
share good valu histor low
valuat longer think case
howev see competit emerg
market gener maker lower labor cost
erod long term
establish firm like israel-bas
teva seen sale declin year
annual sale india-bas aurobindo
sun pharma grew yoy think
due cost advantag
pend combin upjohn may
improv sharehold first
year see deal prevent
long-term declin base fact
upjohn brand lack patent protect
rapidli declin view deal
fail remedi rel high product
cost compar emerg market
target price ep estim
materi histor forward price-to-earnings
averag due integr risk post upjohn
merger expect close
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
chairman board
corpor overview develop licens manufactur market pharmaceut
primarili gener biosimilar varieti therapeut categori compani oper
three segment north america gener total revenu oper incom
europ gener revenu oper incom rest world gener
revenu oper incom
market profil reach peak gross profit margin gener drug industri fell
nearli eight percentag point calcul driven two key factor first annual fda
gener drug approv grew rapidli view due emerg market
firm increas activ market second major retail pharmaci chain drug
wholesal band togeth purchas joint ventur increas negoti power gener
gener price declin due intens competit increas scale custom think
long-term trajectori volum growth posit industri experi two import
demand driver next five ten year includ rapid age develop popul
prime prescript util year particularli estim babi boomer turn
day also rapidli expand middl class gain first-tim access advanc health care
pharmaceut emerg market nation like india china
corpor strategi unlik mani peer mostli produc simpler commodity-lik gener
shift busi toward large-molecul specialti drug biosimilar higher
barrier entri due complex regulatori approv manufactur requir estim
commodity-lik gener gener mylan gener sale
amount fall around compani ramp import new complex gener
biosimilar
exampl recent success complex drug area includ gener copaxon inject
multipl sclerosi drug fda approv fulphila biosimilar neulasta anti-infect
inject cancer patient fda approv wixela inhub gener inhal asthma
major transact juli announc plan spin off-pat
brand drug busi upjohn asset new compani call viatri deal expect
close upjohn sell mani well-known drug like viagra lipitor major
growth driver declin lose patent protect sharehold
viatri whose pro-forma free cash flow around mean
stake deal look good year one better would earn
view given gener year end septemb
trend downward viatri also increas resourc help manag alleg price-fix
opioid litig risk
see viatri earn grow long-term howev without patent protect upjohn
well-known drug rapid declin upjohn sale fell yoy gener brand
lyrica enter market even exclud lyrica upjohn sale includ well-known brand like
lipitor viagra drop yoy upjohn sale downward glide think fall
restor growth continu ramp valuabl complex gener biosimilar think
like though view deal fail address higher product cost
indian-bas gener firm gain market share see emerg market
compani move valu chain complex biosimilar long-term
legal risk current subject numer investig lawsuit
govern competitor case sometim result larg legal liabil may
meaning impact abil make long-term invest sustain growth
pharmaceut busi inform relat case often becom public unexpectedli
creat bout prolong neg sentiment equiti valuat compress march
compani defend number high profil case includ limit follow
name along numer drug manufactur distributor case relat
nation opioid crisi brought multipl government entiti along
gener maker su multipl state allegedli engag widespread gener price fix
illeg market share alloc also name defend class action suit
relat price market epipen auto-injector
financi trend sale aid sever acquisit rose billion billion
repres three-year compound annual growth rate compound-annual-growth-rate howev sale fell
versu advers impact sever gener drug price deflat due intens
competit consolid downstream custom adjust pre-tax incom per share grew
declin repres three-year compound-annual-growth-rate
despit challeng environ gener drug maker recent year leverag
maintain safe though conserv level view ebita-to-interest
materi better peer-averag around
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu usd
neutral sinc februari technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
outlook sub-industri
next year neutral expect
modest revenu growth driven
recent slowdown novel drug approv
potenti new industri price regul
neg partial off-set
upcom period low patent expir
also expect major gener maker continu
struggl due lower-cost emerg
follow banner year novel drug approv
fda signific
slowdown occur think
weigh drug maker revenu growth next
year novel brand drug enter market
gener competit often rival brand
either provid signific boost
revenu firm market
total number fda novel drug
approv fell versu
expect mean less revenu boost
major brand drug maker year ahead
estim sub-industri total
 spend pace
yoy declin septemb like
reflect effort maintain margin
sluggish revenu growth year ahead
addit fewer new brand enter
risk new price rule view
accord studi wall street
govern health system develop
countri like england norway canada
often pay less major drug
medicar kaiser famili foundat
poll indic american feel
drug cost unreason believ
dynam rais pressur drug maker
curtail usual price hike
politician enact polici lower
drug cost voter accordingli sever new
propos lower drug price emerg
side isl recent month
includ bill hous democrat
would allow medicar directli negoti
price drug maker senat
maximum medicar drug plan shift
cost burden drug maker
unclear new propos
enough support becom law see
polit parti increas focu
control drug cost signific risk
weigh outlook
balanc neg factor face
brand drug maker upcom period
low patent expir typic
biggest revenu headwind loss patent
protect open door gener
biosimilar competit base data
evaluatepharma annual global drug sale
risk expir patent averag
total forecast
drop fewer
patent cliff year ahead
major posit brand drug revenu
beyond brand firm make lion
share sub-industri market cap outlook
gener drug firm neg think
india-bas gener maker continu
take market share develop nation
firm due lower product cost
saw occur last year establish firm
like israel-bas teva saw sale
declin year-to-d thru sale
india-bas aurobindo sun pharma
grew yoy think due
rise broader composit
base index
five-year market price perform
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
buy drop price target ep estim
maintain -- histor forward price-to-earnings averag due
mount litig risk share sinc may
expans anti-trust case alleg wide-spread price fix among gener
maker estim gener annual sale alleg
price-fix drug year question potenti liabil case
highli uncertain could signific downgrad reflect view
price-to-earnings multipl remain compress prolong neg sentiment stem
high degre legal uncertainti could take year resolv
despit litig overhang keep hold think share
like oversold follow news liabil ultim prove
manag due ampl free cash flow gener strong ramp sever
first-to-fil gener biosimilar /colin scarola
pm et cfra maintain opinion share gener drug maker
share firm involv gener drug includ teva
sharpli today follow
expans anti-trust lawsuit three firm subsidiari
alreadi name one defend relat on-going case origin
alleg illeg price fix drug may file
expand alleg defend firm involv mani drug
teva gener state claim without merit
plan defend alleg present materi risk
gener maker think risk much today
last week alleg relat case alreadi
underway sever year process like take sever year
conclus forward price-to-earnings multipl alreadi
long-term averag last week think risk alreadi price
analyst research note compani news
et cfra maintain hold opinion share
keep target new ep estim --
myl histor forward price-to-earnings averag due integr risk post
upjohn merger expect close intensifi gener
competit maintain ep estim initi
estim adjust ep beat consensu
revenu grew yoy driven mainli stronger expect sale
rest world revenu yoy due higher volum
exist product sold emerg market new product sale mainli
australia india grow much slower compar previou quarter
north america sale yoy revenu due weaker sale
exist product loss exclus tadalafil partial off-set new
product sale wixela inhub gener competit intensifi
 low cost foreign gener produc gain market share pose
seriou threat exist player view /sel hardi
et cfra rais opinion share hold sell
maintain price target expect
long-term pressur gener drug price volum
base market share gain see india-bas gener drug firm make
 larg develop nation firm like israel-bas teva
struggl gener revenu growth view ytd revenu
india-bas aurobindo sun pharma grew yoy think
product cost advantag also see downstream consolid health
provid insur pharmaci benefit manger reduc price power
asid fundament view week bloomberg report gener
maker talk doj resolv probe alleg price-fix
litig outcom highli unpredict view clariti could
materi boost investor sentiment despit neg long-term fundament
outlook hold opinion reflect conflict dynam /colin scarola
et cfra lower opinion share sell hold
drop target ep estim --
histor forward price-to-earnings averag maintain ep estim
drop adjust ep vs beat
consensu revenu grew yoy led north america
revenu yoy recent launch wixela yupelri overcom
sustain gener price volum pressur view low
cost foreign produc gain market share despit roughli flat
revenu ytd thru ytd adjust ep adjust free cash flow
yoy respect driven foreign competit
view manag tout pend combin upjohn unit
strategi stabil current declin yet given upjohn sale
current fall pace yoy see high risk deal
under-perform expect expect share outperform
et cfra lower opinion share hold buy
keep target ep estim
unchang histor forward price-to-earnings averag due signific
litig risk competit lower-cost indian drug maker today
announc plan spin off-pat brand drug
busi upjohn asset yet unnam new compani
sharehold newco whose pro-forma free cash flow
around mean stake think well
deal better would earn
view given trail year downward trend
deal also increas resourc manag alleg price-fix litig risk
on-going market share loss india-bas competit view given
magnitud risk howev think long-term growth opportun
limit see share near fair valu adjust recommend
pm et cfra lower opinion share buy strong
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
